EULAR 2023 Lupus Highlights
Rheumnow Podcast
00:00
The Future of Liposeritimatosis Therapy
The primary endpoint was meeting SRI for response as well as a reduction in order to partner alone less or equals to 10 milligram per day. The study tells us that both by adding BTK inhibitor to Upada Sitinib because both have a different signaling pathways, do not make any difference in terms of efficacy compared to placebo versus Upada sitinib. This promising efficacy trials will advance to face-free trials. However, it was still unclear whether the company will go ahead with Upada satinib alone or will test both compounds in a face-free trial.
Transcript
Play full episode
